In Q1 of fiscal 2027, the quarter ended Jun 30, 2026, VivoSim Labs, Inc. reported revenue of $18,000. It recorded a net loss of $1.3 million. The operating loss came to $2.8 million, an operating margin of -15327.8%. Diluted earnings per share were -$0.25.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Jun 30, 2026
|
Q1 FY2027
Jun 30, 2026
|
Q1 FY2025
Jun 30, 2025
|
Q4 FY2025
Mar 31, 2025
|
Q3 FY2025
Dec 31, 2024
|
Q2 FY2025
Sep 30, 2024
|
Q3 FY2023
Dec 31, 2023
|
Q2 FY2023
Sep 30, 2023
|
Q1 FY2023
Jun 30, 2023
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Cost of revenue |
—
|
—
|
—
|
0
|
0
|
0
|
—
|
—
|
—
|
| Gross profit |
—
|
—
|
—
|
0
|
0
|
0
|
—
|
—
|
—
|
| Research and development |
—
|
1
|
1
|
1
|
2
|
1
|
1
+54.9%
|
1
+96.6%
|
2
+187.2%
|
| Selling, general and administrative |
—
|
2
|
2
|
2
|
2
|
2
|
2
-12.5%
|
3
-1.7%
|
3
+31.6%
|
| Operating income |
—
|
-3
|
-3
|
-3
|
-3
|
-3
|
-4
-5.1%
|
-4
-17.3%
|
-4
-63.9%
|
| Income tax |
—
|
0
|
0
|
0
|
0
|
0
|
0
-100.0%
|
0
|
0
|
| Net income |
—
|
-1
|
-3
|
7
|
-3
|
-3
|
-4
-3.0%
|
-4
-14.0%
|
-4
-59.1%
|
| Basic EPS |
—
|
-0.25
|
-1.14
|
4.21
|
-2.28
|
-1.68
|
-0.40
|
-0.46
|
-0.46
|
| Diluted EPS |
—
|
-0.25
|
-1.14
|
4.21
|
-2.28
|
-1.68
|
-0.40
|
-0.46
|
-0.46
|
| Weighted average shares, basic |
—
|
5
|
3
|
2
|
2
|
1
|
9
|
9
|
9
|
| Weighted average shares, diluted |
—
|
5
|
3
|
2
|
2
|
1
|
9
|
9
|
9
|
| Other measures | |||||||||
| Depreciation and amortization |
—
|
0
|
0
|
0
|
0
|
0
|
0
+91.9%
|
0
+108.8%
|
0
+168.0%
|
| EBITDA |
—
|
-3
|
-3
|
-3
|
-3
|
-3
|
-4
-4.2%
|
-4
-16.4%
|
-4
-62.9%
|
| Interest coverage |
—
|
-689.75x
|
-728.75x
|
-630.80x
|
-693.60x
|
—
|
—
|
—
|
—
|
| Margins | |||||||||
| Gross margin |
—
|
—
|
—
|
100.00%
|
91.67%
|
96.67%
|
—
|
—
|
—
|
| Operating margin |
—
|
-15,327.78%
|
-7,878.38%
|
-6,184.31%
|
-14,450.00%
|
-8,693.33%
|
-73,600.00%
|
—
|
-5,593.33%
|
| Profit margin |
—
|
-7,433.33%
|
-7,683.78%
|
13,435.29%
|
-14,362.50%
|
-8,496.67%
|
-72,080.00%
|
—
|
-5,370.67%
|
| EBITDA margin |
—
|
-15,105.56%
|
-7,713.51%
|
-6,064.71%
|
-14,170.83%
|
-8,436.67%
|
-72,180.00%
|
—
|
-5,504.00%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- VIVS (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1497253
- Former names
- ORGANOVO HOLDINGS, INC. (until Apr 23, 2025); REAL ESTATE RESTORATION & RENTAL, INC. (until Oct 31, 2011)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.